Beta Bionics Inc Stock News

IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2026 and updated its full year guidance for the year ending December 31, 2026.

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system.

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase pr...

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per sh...

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $125.0 million of shares of its common stock. All of the shares are being offered by Beta Bionics. In addition, Beta Bionics intends to grant the underwriters for the offering a 30-d...

IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company's patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leadin...